8-K filed Nov 4, 2026 at 16:13 ET
Acadia Pharmaceuticals reported Q3 2026 GAAP total revenues of $342M, up 22% YoY on a non-GAAP adjusted basis, and GAAP diluted EPS of $0.31, which beat the $0.18 consensus. DAYBUE net sales grew 39% YoY to $140M, driven by DAYBUE STIX uptake. The company raised its 2026 DAYBUE guidance to $505-$520M and narrowed total revenue guidance to $1.265-$1.295B, while net income declined to $54M from $72M in the prior year due to higher SG&A and a large income tax expense.